Several frequently mutated residues in Ibrutinib-resistant CLL, including PLCγ2 S707, L845, D993 and M1141, are likely to impact on PLC activity via the same mechanism. Here, PLCG2 is linked to B-cell chronic lymphocytic leukemia.